Latest news and press releases about Karyopharm Therapeutics Inc. (KPTI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses.
Price
| Price | $1.70 |
| Market Cap | $39M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.13 |
| EV / EBITDA | -1.15 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 77.63% |
| Return on Invested Capital | 376.87% |
| Return on Assets | -201.89% |
| Gross Margin | 95.88% |
| Operating Margin | -56.17% |
| Net Margin | -153.28% |
Related companies: ALGS · BRNS · CVM · FGEN · INMB · MDCX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of KPTI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks